Baxter International | BAX - Assets


Baxter International reported $19.41B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Abbott USD 108.25B 968M Sep/2026
AngioDynamics USD 269.68M 4.04M Sep/2025
Artivion USD 1.04B 29.85M Sep/2026
AtriCure USD 717.54M 40.89M Sep/2026
Baxter International USD 19.41B 377M Sep/2026
Becton, Dickinson and Co. USD 50.79B 60M Sep/2026
Boston Scientific USD 45.46B 245M Sep/2026
Cooper Companies USD 12.67B 191.1M Jun/2026
Dexcom USD 6.24B 216.5M Sep/2026
Edwards Lifesciences USD 14.14B 277.3M Sep/2026
Fresenius EUR 42.24B 401M Sep/2026
Globus Medical USD 5.53B 39.93M Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
ICU Medical USD 3.94B 27.48M Sep/2026
Inogen USD 307.01M 5.03M Sep/2025
Insulet USD 3.42B 250M Sep/2026
Integra LifeSciences USD 3.51B 55.69M Sep/2026
Intuitive Surgical USD 19.35B 1.53B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Laboratory Of America USD 18.92B 392.3M Sep/2026
Medtronic USD 93.31B 278M Jun/2026
Merit Medical Systems USD 2.92B 61.29M Sep/2026
Quest Diagnostics USD 17.22B 282M Sep/2026
Smith & Nephew USD 11.01B 321M Jun/2026
Stryker USD 47.25B 683M Sep/2026
Tandem Diabetes Care USD 1.16B 5.29M Sep/2026
Teleflex USD 6.35B 438.92M Sep/2026
Terumo JPY 2.37T 61.86B Jun/2026
Zimmer Biomet Holdings USD 23.54B 740.8M Sep/2026